Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III
Interventions: DRUG: Paclitaxel|DRUG: Perjeta|DRUG: Herceptin SC|DRUG: Tamoxifen|DRUG: Letrozole|DRUG: LHRH agonist|DRUG: FEC|DRUG: Carboplatin
Sponsor: University of Chicago